Cargando…

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

BACKGROUND: While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trujillo, Jonathan A., Luke, Jason J., Zha, Yuanyuan, Segal, Jeremy P., Ritterhouse, Lauren L., Spranger, Stefani, Matijevich, Karen, Gajewski, Thomas F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839232/ https://www.ncbi.nlm.nih.gov/pubmed/31703593 http://dx.doi.org/10.1186/s40425-019-0780-0

Ejemplares similares

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
por: Spranger, Stefani, et al.
Publicado: (2014)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
por: Luke, Jason J., et al.
Publicado: (2016)

Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma
por: Zha, Yuanyuan, et al.
Publicado: (2015)

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
por: Spranger, Stefani, et al.
Publicado: (2015)

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling
por: Spranger, Stefani, et al.
Publicado: (2015)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Rational combinations of immunotherapeutics that target discrete pathways
por: Spranger, Stefani, et al.
Publicado: (2013)

Tumor-intrinsic oncogene pathways mediating immune avoidance
por: Spranger, Stefani, et al.
Publicado: (2015)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
por: Sweis, Randy F, et al.
Publicado: (2015)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
por: Bao, Riyue, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

A nano-enhanced vaccine for metastatic melanoma immunotherapy
por: Salotto, Katelyn E., et al.
Publicado: (2022)

WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner
por: Brown, K, et al.
Publicado: (2017)

β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma
por: Francis, Jeffrey C., et al.
Publicado: (2013)

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
por: Cabrita, Rita, et al.
Publicado: (2020)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy
por: Fadel, Celine A, et al.
Publicado: (2022)

Hydrocephalus caused by conditional ablation of the Pten or beta-catenin gene
por: Ohtoshi, Akihira
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_aop0bm3v4c4tjqtippd0qqbrcf